肠道微生物群及其衍生物与心力衰竭关系的研究进展

摘要/Abstract

摘要： 心力衰竭（HF）发生于心血管系统疾病的终末阶段,目前对于其治疗虽已取得显著进展,但在世界范围内仍存在较高的死亡率和发病率。因此,了解心力衰竭的发病机制至关重要。根据目前的研究结果发现,心衰患者一般都存在肠道微生物群的紊乱,且不同类型的心衰其肠道微生物群紊乱的表现非常相似。本文针对已报道的与心衰相关的肠道微生物群及其衍生物,对其研究进展在此进行综述。

王璐, 孙玉芹. 肠道微生物群及其衍生物与心力衰竭关系的研究进展[J]. 心血管病防治知识, 2022, 12(15): 92-94.

[1] 刘洋,赵冬梅,尹兴忠,等.心衰发病机制的研究进展[J].医学信息,2017,30(18):23-24.
[2] McMurrayJJ, AdamopoulosS, AnkerSD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2012,33(14):1787-1847.
[3] 周京敏, 崔晓通, 葛均波. 中国心力衰竭的流行病学概况[J].中华心血管病杂志,2015,43(12):1018-1021.
[4] 刘鸿程, 宋光. 肠道菌群在溃疡性结肠炎中的研究进展[J].医学综述, 2020, 26(14): 2819-2823.
[5] Ni J, Wu GD, Albenberg L, et al.Gut microbiota and IBD: causation or correlation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(10): 573-584.
[6] Rooks MG, Garrett WS.Gut microbiota, metabolites and host immunity[J]. Nat Rev Immunol, 2016, 16(6): 341-352.
[7] Pickard JM, Zeng MY, Caruso R, et al.Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease[J]. Immunol Rev, 2017, 279(1): 70-89.
[8] 张琳琳. 肠道菌群与肥胖[J].浙江临床医学,2021,23(1):146-148.
[9] Mehta NN,Mcgillicuddy FP.Experimental endotoxemia induces adipose inflammation and insulin resistance in humans[J].Diabetes,2010,59(1):172-181.
[10] Jie Z, Xia H, Zhong SL, et al.The gut microbiome in atherosclerotic cardiovascular disease[J].Nat Commun,2017,8(1):845.
[11] 王丽君,谢莲娜,周雪,等.急性心肌梗死患者肠道菌群多样性分析[J].中国微生态学杂志,2017,29(10):1164-1168.
[12] Pevsner-Fischer M, Blacher E, Tatirovsky E,et al.The gut microbiome and hypertension[J].Curr Opin Nephrol Hypertens,2017,26(1):1-8.
[13] Kitai T, Kirsop J, Tang WH.Exploring the microbiome in heart failure[J].Curr Heart Fail Rep,2016,13(2):103-109.
[14] 宋勇战,钱明阳,李渝芬,等.怀有先天性心脏病胎儿的孕妇与正常孕妇肠道菌群的高通量测序分析[J].中国病理生理杂志,2015,31(04):702-706.
[15] Hooper, LV, Littman, DR. Macpherson, A J. Interactions between the microbiota and the immune system[J]. Science, 336,1268-1273 (2012).
[16] Nicholson JK, Holmes E, Kinross J, et al.Host-gut microbiota metabolic interactions[J]. Science, 336, 1262-1267 (2012).
[17] Cui X, Ye L, Li J, et al.Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients[J]. Sci Rep, 2018, 8: 635.
[18] Deitch EA.Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings[J]. Surgery, 2002, 131(3): 241-244.
[19] Cirera I, Martin Bauer T, Navasa M, et al.Bacterial translocation of enteric organisms in patients with cirrhosis[J]. J Hepatol, 2001, 34(1): 32-37.
[20] Sandek A, Swidsinski A, Schroedl W,et al.Intestinal blood flow in patients with chronic heart failure:a link with bacterial growth,gastrointestinal symptoms,and cachexia[J].J AmColl Cardiol,2014,64(11):1092-1102.
[21] Levine B, Kalman J, Mayer L, et al.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990, 323(4): 236-241.
[22] Kitai T, Kirsop J, Tang WH.Exploring the microbiome in heart failure[J].Curr Heart Fail Rep,2016,13(2):103-109.
[23] Abbasi J .TMAO and Heart Disease: The New Red Meat Risk[J]. JAMA, 2019, 321(22).
[24] Ierardi E, Sorrentino C, Principi M, et al.Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario[J]. Hepatobiliary Surg Nutr, 2015, 4: 289-92.
[25] Organ CL, Otsuka H, Bhushan S, et al.Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure[J]. Circ Heart Fail, 2016, 9: e002314.
[26] Bogiatzi C,Gloor G,Allen-Vercoe E,et al.Metabolic products of the intestinal microbiome and extremes of atherosclerosis[J].Atherosclerosis, 2018, 273: 91-97.
[27] Chen S, Jiang P P, Yu D, et al.Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial[J]. European Journal of Nutrition, 2020,60(2):747-758.
[28] Aldana-Hernández P,Leonard KA,Zhao YY,et al.Dietary choline or trimethylamine N-oxide supplementation does not influence atherosclerosis development in Ldlr-/- and Apoe-/- male mice[J].J Nutr,2020,150(2):249-255.
[29] Chen K, Zheng X, Feng M, et al.Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide Contributes to Cardiac Dysfunction in Western Diet-Induced Obese Mice[J]. Front Physiol,2017,8: 139.
[30] Conraads V M,Jorens PG,De Clerck LS,et al.Selective intestinal deconta mination in advanced chronic heart failure:a pilot trial[J].Eur J Heart Fail,2004,6(4):483-491.
[31] De Leon LM, Watson JB, Kelly CR, et al.Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection[J]. Clin Gastroenterol Hepatol,2013, 11(8): 1036-1038.

肠道微生物群及其衍生物与心力衰竭关系的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨振. 益气活血法对老年气虚血瘀型失代偿期慢性心力衰竭患者心功能及血清NT-proBNP、CysC的影响[J]. 心血管病防治知识, 2023, 13(9): 28-30.
[2]	上官黎明, 张海誉. 贝那普利片联合美托洛尔片对高血压合并心力衰竭患者心功能及血GMP-140、CT-1水平的影响[J]. 心血管病防治知识, 2023, 13(9): 31-33.
[3]	罗玉梅. 芪红汤联合芪参益气滴丸治疗冠心病慢性心力衰竭的疗效观察[J]. 心血管病防治知识, 2023, 13(8): 19-21.
[4]	上官昌瑾. 生脉苓桂救心汤在改善老年射血分数降低型心力衰竭中医证候中的应用[J]. 心血管病防治知识, 2023, 13(8): 26-29.
[5]	赖少云. 全面护理在ICU心力衰竭患者中的效果观察及有效率分析[J]. 心血管病防治知识, 2023, 13(8): 33-36.
[6]	庞建萍, 李少枝, 贺青军. 基于纽曼系统的多学科协作健康教育在慢性心力衰竭患者中的应用[J]. 心血管病防治知识, 2023, 13(8): 49-52.
[7]	刘晓艳. 沙库巴曲缬沙坦治疗扩张型心肌病并慢性心力衰竭患者的研究[J]. 心血管病防治知识, 2023, 13(7): 3-5.
[8]	叶小婷, 吴丽钦, 吕淑贞. 利拉鲁肽联合延续性护理对老年慢性心力衰竭伴糖尿病患者心功能及生活质量的影响研究[J]. 心血管病防治知识, 2023, 13(7): 82-84.
[9]	卢丽华. 心肌收缩力储备联合心脏彩超对高龄慢性心力衰竭患者预后的预测效能研究[J]. 心血管病防治知识, 2023, 13(6): 6-8.
[10]	李琼利. 系统化护理干预对连续性血液净化治疗肾衰竭合并重症心力衰竭患者的效果影响[J]. 心血管病防治知识, 2023, 13(6): 36-38.
[11]	许莎琴. 基于微信平台辅助延续性护理结合家庭护理对慢阻肺合并心力衰竭患者依从性的影响[J]. 心血管病防治知识, 2023, 13(6): 52-55.
[12]	周茜. 重组人脑利钠肽联合参附注射液治疗急性心肌梗死合并心力衰竭的效果分析[J]. 心血管病防治知识, 2023, 13(5): 3-5.
[13]	任耒. 一体化急救护理模式对重症肺炎合并心力衰竭患者心肺功能的影响[J]. 心血管病防治知识, 2023, 13(5): 42-45.
[14]	钟春燕. 慢性心力衰竭患者血清 IL-1β、TNF-α、CTRP5的变化及临床意义[J]. 心血管病防治知识, 2023, 13(5): 21-24.
[15]	柯艳红. 多方位护理干预对慢性心力衰竭患者遵医行为和生活质量的影响[J]. 心血管病防治知识, 2023, 13(4): 51-53.